Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

PERAMEDIC Personalised Adaptive Medicine

Coordinator
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV, Germany
Runs
1 February 2024 to 31 January 2027
Status
Running
EU funding
€1.7m
Total cost
€1.7m
Partners
6 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101130241

What the project is doing

In the project's own words, from its summary on CORDIS.

Personalised drug formulation is a hot topic but state of the art approaches are limited by low scalability, cost, and regulatory hurdles, while current polypill formulation efforts are hindered by liquid form or hot melt addition approaches, posing stability issues. These bottlenecks carry a great societal price, as the synergic boost of drug combinations was recently demonstrated to reach significant improvement in treatment outcomes, while keeping active substances in the ideal physiological concentration window is known to maximise efficiency and reduce side effects.

Also, polypharmacy is a real problem leading to dosing errors and significant loss in patient adherence. Finally, while Big Data Health IT system concepts on the far horizon hold potential to gather the large amount of reliable dosage-patient data required for evidence-based personalised medicine, the technology to deliver such data – well-tracked patient/dosing procedures with bi-directional digital information flow – is missing.

The PERAMEDIC project proposes to resolve these problems with a breakthrough solution: a stand-alone drug formulation system for personalised medicine, offering locally prepared, individually customised, segmented release polypills, with an inherently digital technology interface. The system relies on integrating several novel technologies: personal release profiles, in situ 3D printing of release matrix using adaptive toolpaths, and ultra-precise multichannel powder dosing of drugs into sealed microcompartments.

The envisaged device would be a desktop-size pill/capsule printing machine, using canisters of powdered drugs and bioresorbable polymer matrix material. Application scenarios would be first clinical settings, then at later stage, pharmacy locations and medical practices such as GP’s office. PERAMEDIC will deliver a lab-scale proof-of-concept prototype system of the functionally combined novel technologies, with a preview design of the future technology.

Topics

Who is involved

OrganisationCityCountryRole
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyCoordinator
Ats Advisory SRLBruxelles / BrusselBelgiumParticipant
Bulkai Tanacsado KftBudapestHungaryParticipant
Loughborough UniversityLoughboroughUnited KingdomAssociatedpartner
The University of LiverpoolLiverpoolUnited KingdomAssociatedpartner
University of East AngliaNorwichUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI